Download PDF
Semin Thromb Hemost 2013; 39(04): 356-364
DOI: 10.1055/s-0033-1334487
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

Paul J. Declerck
1   Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium
,
Ann Gils
1   Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
16 March 2013 (online)

    Permissions and Reprints

Abstract

Plasminogen activator inhibitor 1 (PAI-1) is the main inhibitor of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator and therefore plays an important role in the plasminogen–plasmin system. PAI-1 is involved in a variety of cardiovascular diseases (mainly through inhibition of t-PA) as well as in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). PAI-1 is a unique member of the serpin superfamily, exhibiting particular unique conformational and functional properties. Because of its involvement in various biologic and pathophysiologic processes, PAI-1 has been the subject of many studies, including extensive structural investigations, in vitro cell biologic studies, in vivo animal studies, and epidemiologic studies. The review provides an overview on the current knowledge on PAI-1.

Keywords

plasminogen activator inhibitor 1 - PAI-1 - fibrinolysis - cancer - plasminogen activation - serpin
 

  • References

  • 1 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (1) 4-13
    CrossrefPubMedSearch in Google Scholar
  • 2 Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5 (Suppl. 01) 132-142
    CrossrefPubMedSearch in Google Scholar
  • 3 Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008; 214 (3) 283-293
    CrossrefPubMedSearch in Google Scholar
  • 4 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A 1983; 80 (10) 2956-2960
    CrossrefPubMedSearch in Google Scholar
  • 5 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44 (2) 139-143
    CrossrefPubMedSearch in Google Scholar
  • 6 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68 (1) 1-19
    CrossrefPubMedSearch in Google Scholar
  • 7 Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56 (1–2) 104-132
    CrossrefPubMedSearch in Google Scholar
  • 8 Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3 (8) 1879-1883
    CrossrefPubMedSearch in Google Scholar
  • 9 Andreasen PA, Riccio A, Welinder KG , et al. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 1986; 209 (2) 213-218
    CrossrefPubMedSearch in Google Scholar
  • 10 Ginsburg D, Zeheb R, Yang AY , et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78 (6) 1673-1680
    CrossrefPubMedSearch in Google Scholar
  • 11 Pannekoek H, Veerman H, Lambers H , et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986; 5 (10) 2539-2544
    PubMedSearch in Google Scholar
  • 12 Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83 (18) 6776-6780
    CrossrefPubMedSearch in Google Scholar
  • 13 Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73 (2) 459-468
    CrossrefPubMedSearch in Google Scholar
  • 14 Mimuro J, Sawdey M, Hattori M, Loskutoff DJ. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1). Nucleic Acids Res 1989; 17 (21) 8872
    CrossrefPubMedSearch in Google Scholar
  • 15 Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol 1990; 10 (3) 1265-1269
    PubMedSearch in Google Scholar
  • 16 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterization of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisae. Fibrinolysis 1992; 6: 263-272
    PubMedSearch in Google Scholar
  • 17 Bijnens AP, Knockaert I, Cousin E, Kruithof EK, Declerck PJ. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1. Thromb Haemost 1997; 77 (2) 350-356
    PubMedSearch in Google Scholar
  • 18 Meissenheimer LM, Verbeke K, Declerck PJ, Gils A. Quantitation of vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. Thromb Haemost 2006; 95 (5) 902-903
    PubMedSearch in Google Scholar
  • 19 Xue Y, Björquist P, Inghardt T , et al. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 1998; 6 (5) 627-636
    CrossrefPubMedSearch in Google Scholar
  • 20 Gils A, Pedersen KE, Skottrup P , et al. Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 2003; 90 (2) 206-217
    PubMedSearch in Google Scholar
  • 21 Lawrence D, Strandberg L, Grundström T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186 (3) 523-533
    CrossrefPubMedSearch in Google Scholar
  • 22 Van De Craen B, Scroyen I, Vranckx C , et al. Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. Thromb Res 2012; 129 (4) e126-e133
    CrossrefPubMedSearch in Google Scholar
  • 23 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74 (4) 1465-1472
    CrossrefPubMedSearch in Google Scholar
  • 24 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31 (3) 427-436
    CrossrefPubMedSearch in Google Scholar
  • 25 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115
    PubMedSearch in Google Scholar
  • 26 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70 (3) 327-333
    CrossrefPubMedSearch in Google Scholar
  • 27 Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71 (1) 220-225
    CrossrefPubMedSearch in Google Scholar
  • 28 Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70 (5) 1645-1653
    PubMedSearch in Google Scholar
  • 29 Owensby DA, Morton PA, Wun TC, Schwartz AL. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 1991; 266 (7) 4334-4340
    PubMedSearch in Google Scholar
  • 30 Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev 1990; 32 (3) 287-292
    CrossrefPubMedSearch in Google Scholar
  • 31 Declerck PJ, De Mol M, Alessi MC , et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263 (30) 15454-15461
    PubMedSearch in Google Scholar
  • 32 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260 (21) 11581-11587
    PubMedSearch in Google Scholar
  • 33 Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ Res 1990; 67 (5) 1281-1286
    CrossrefPubMedSearch in Google Scholar
  • 34 Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267 (17) 11693-11696
    PubMedSearch in Google Scholar
  • 35 Urano T, Strandberg L, Johansson LBA, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209 (3) 985-992
    CrossrefPubMedSearch in Google Scholar
  • 36 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202 (1) 29-37
    CrossrefPubMedSearch in Google Scholar
  • 37 De Taeye B, Gils A, Declerck PJ. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. Thromb Haemost 2004; 92 (5) 898-924
    PubMedSearch in Google Scholar
  • 38 Mottonen J, Strand A, Symersky J , et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355 (6357) 270-273
    CrossrefPubMedSearch in Google Scholar
  • 39 Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol 1995; 2 (10) 891-897
    CrossrefPubMedSearch in Google Scholar
  • 40 Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297 (3) 683-695
    CrossrefPubMedSearch in Google Scholar
  • 41 Sharp AM, Stein PE, Pannu NS , et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7 (2) 111-118
    CrossrefPubMedSearch in Google Scholar
  • 42 Jensen JK, Thompson LC, Bucci JC , et al. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011; 286 (34) 29709-29717
    CrossrefPubMedSearch in Google Scholar
  • 43 Lin Z, Jiang L, Yuan C , et al. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 2011; 286 (9) 7027-7032
    CrossrefPubMedSearch in Google Scholar
  • 44 Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62 (2) 748-751
    PubMedSearch in Google Scholar
  • 45 Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224 (1) 125-134
    CrossrefPubMedSearch in Google Scholar
  • 46 Boncela J, Papiewska I, Fijalkowska I, Walkowiak B, Cierniewski CS. Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J Biol Chem 2001; 276 (38) 35305-35311
    CrossrefPubMedSearch in Google Scholar
  • 47 Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14 (13) 2969-2977
    PubMedSearch in Google Scholar
  • 48 Vleugels N, Gils A, Mannaerts S, Knockaert I, Declerck PJ. Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. Fibrinolysis & Proteolysis. 1998; 12: 277-282
    CrossrefPubMedSearch in Google Scholar
  • 49 Dewilde M, Strelkov SV, Rabijns A, Declerck PJ. High quality structure of cleaved PAI-1-stab. J Struct Biol 2009; 165 (2) 126-132
    CrossrefPubMedSearch in Google Scholar
  • 50 Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J Mol Biol 2001; 305 (4) 773-783
    CrossrefPubMedSearch in Google Scholar
  • 51 Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003; 2 (1) 19-28
    PubMedSearch in Google Scholar
  • 52 Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265 (22) 13029-13035
    PubMedSearch in Google Scholar
  • 53 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78 (5) 1254-1261
    PubMedSearch in Google Scholar
  • 54 Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276 (19) 15567-15570
    CrossrefPubMedSearch in Google Scholar
  • 55 Carrell R, Travis J. Alpha-1-antitrypsin and the serpins - variation and countervariation. Trends Biochem Sci 1985; 10: 20-24
    CrossrefPubMedSearch in Google Scholar
  • 56 Sherman PM, Lawrence DA, Yang AY , et al. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 1992; 267 (11) 7588-7595
    PubMedSearch in Google Scholar
  • 57 Sherman PM, Lawrence DA, Verhamme IM, Paielli D, Shore JD, Ginsburg D. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem 1995; 270 (16) 9301-9306
    CrossrefPubMedSearch in Google Scholar
  • 58 Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010; 125 (5) 377-381
    CrossrefPubMedSearch in Google Scholar
  • 59 De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5 (2) 149-154
    CrossrefPubMedSearch in Google Scholar
  • 60 Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236 (4) 425-432
    CrossrefPubMedSearch in Google Scholar
  • 61 Juhan-Vague I, Alessi MC, Declerck PJ. Pathophysiology of fibrinolysis. Baillieres Clin Haematol 1995; 8 (2) 329-343
    CrossrefPubMedSearch in Google Scholar
  • 62 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-1563
    CrossrefPubMedSearch in Google Scholar
  • 63 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342 (8879) 1076-1079
    CrossrefPubMedSearch in Google Scholar
  • 64 Nilsson IM, Ljungnér H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985; 290 (6480) 1453-1456
    CrossrefPubMedSearch in Google Scholar
  • 65 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105 (2) 265-270
    PubMedSearch in Google Scholar
  • 66 Schulman S, Wiman B. Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75 (4) 607-611
    PubMedSearch in Google Scholar
  • 67 Siemens HJ, Brueckner S, Hagelberg S, Wagner T, Schmucker P. Course of molecular hemostatic markers during and after different surgical procedures. J Clin Anesth 1999; 11 (8) 622-629
    CrossrefPubMedSearch in Google Scholar
  • 68 Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97 (3) 336-342
    PubMedSearch in Google Scholar
  • 69 Sandford RM, Bown MJ, London NJ, Sayers RD. The genetic basis of abdominal aortic aneurysms: a review. Eur J Vasc Endovasc Surg 2007; 33 (4) 381-390
    CrossrefPubMedSearch in Google Scholar
  • 70 Mesters RM, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75 (6) 902-907
    Thieme ConnectPubMedSearch in Google Scholar
  • 71 Kornelisse RF, Hazelzet JA, Savelkoul HF , et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173 (5) 1148-1156
    CrossrefPubMedSearch in Google Scholar
  • 72 Arnman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76 (5) 487-499
    CrossrefPubMedSearch in Google Scholar
  • 73 Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007; 27 (6) 1231-1237
    CrossrefPubMedSearch in Google Scholar
  • 74 Narayanaswamy M, Wright KC, Kandarpa K. Animal models for atherosclerosis, restenosis, and endovascular graft research. J Vasc Interv Radiol 2000; 11 (1) 5-17
    CrossrefPubMedSearch in Google Scholar
  • 75 Schneiderman J, Sawdey MS, Keeton MR , et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89 (15) 6998-7002
    CrossrefPubMedSearch in Google Scholar
  • 76 Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16 (4) 539-545
    CrossrefPubMedSearch in Google Scholar
  • 77 Lupu F, Bergonzelli GE, Heim DA , et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13 (7) 1090-1100
    CrossrefPubMedSearch in Google Scholar
  • 78 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151 (9) 1721-1731
    CrossrefPubMedSearch in Google Scholar
  • 79 Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94 (9) 2057-2063
    CrossrefPubMedSearch in Google Scholar
  • 80 Thögersen AM, Jansson JH, Boman K , et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-2247
    CrossrefPubMedSearch in Google Scholar
  • 81 Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21 (4) 611-617
    CrossrefPubMedSearch in Google Scholar
  • 82 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46 (5) 860-867
    CrossrefPubMedSearch in Google Scholar
  • 83 Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 1998; 30 (8) 1535-1543
    CrossrefPubMedSearch in Google Scholar
  • 84 Schafer K, Müller K, Hecke A , et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23 (11) 2097-2103
    CrossrefPubMedSearch in Google Scholar
  • 85 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268 (15) 10739-10745
    PubMedSearch in Google Scholar
  • 86 Ringelstein M, Jung A, Berger K , et al. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol 2012; 259 (11) 2287-2292
    CrossrefPubMedSearch in Google Scholar
  • 87 Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008; 122 (6) 736-742
    CrossrefPubMedSearch in Google Scholar
  • 88 Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002; 126 (11) 1401-1404
    PubMedSearch in Google Scholar
  • 89 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83 (5) 1747-1752
    CrossrefPubMedSearch in Google Scholar
  • 90 Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008; 14 (6) 1255-1260
    CrossrefPubMedSearch in Google Scholar
  • 91 Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90 (1) 204-208
    PubMedSearch in Google Scholar
  • 92 Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W, Ruan CG. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis 2005; 16 (1) 79-84
    CrossrefPubMedSearch in Google Scholar
  • 93 Jänicke F, Schmitt M, Pache L , et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24 (3) 195-208
    CrossrefPubMedSearch in Google Scholar
  • 94 Knoop A, Andreasen PA, Andersen JA , et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77 (6) 932-940
    CrossrefPubMedSearch in Google Scholar
  • 95 Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343 (8889) 117
    CrossrefPubMedSearch in Google Scholar
  • 96 Konecny G, Untch M, Pihan A , et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7 (6) 1743-1749
    PubMedSearch in Google Scholar
  • 97 Kuhn W, Schmalfeldt B, Reuning U , et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999; 79 (11-12) 1746-1751
    CrossrefPubMedSearch in Google Scholar
  • 98 Komiyama S, Aoki D, Saitoh E, Komiyama M, Udagawa Y. Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma. Eur J Gynaecol Oncol 2011; 32 (6) 611-614
    PubMedSearch in Google Scholar
  • 99 Becker M, Szarvas T, Wittschier M , et al. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer 2010; 116 (19) 4502-4512
    CrossrefPubMedSearch in Google Scholar
  • 100 Gao S, Nielsen BS, Krogdahl A , et al. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer 2010; 49 (6) 526-538
    PubMedSearch in Google Scholar
  • 101 Halamkova J, Kiss I, Pavlovsky Z , et al. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 2011; 58 (112) 1918-1925
    PubMedSearch in Google Scholar
  • 102 Durand MK, Bødker JS, Christensen A , et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91 (3) 438-449
    PubMedSearch in Google Scholar
  • 103 McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36 (3-4) 184-194
    PubMedSearch in Google Scholar
  • 104 Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 2008; 118 (2) 116-124
    CrossrefPubMedSearch in Google Scholar
  • 105 Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82 (10) 1702-1708
    CrossrefPubMedSearch in Google Scholar
  • 106 Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 2008; 100 (6) 1037-1040
    PubMedSearch in Google Scholar
  • 107 Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60 (20) 5839-5847
    PubMedSearch in Google Scholar
  • 108 Brodsky S, Chen J, Lee A, Akassoglou K, Norman J, Goligorsky MS. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 2001; 281 (4) H1784-H1792
    PubMedSearch in Google Scholar
  • 109 Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276 (11) 8135-8141
    CrossrefPubMedSearch in Google Scholar
  • 110 Czekay R-P, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 2004; 229 (11) 1090-1096
    PubMedSearch in Google Scholar
  • 111 Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013; 39 (4) 382-391
    Thieme ConnectPubMedSearch in Google Scholar
  • 112 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3 (1) 35-45
    CrossrefPubMedSearch in Google Scholar
  • 113 Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28 (5) e72-e91
    CrossrefPubMedSearch in Google Scholar
  • 114 Lijnen HR, Juhan-Vague I. The fibrinolytic system and obesity. Thromb Haemost 2002; 88 (5) 882
    PubMedSearch in Google Scholar
  • 115 Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20 (4) 1150-1154
    CrossrefPubMedSearch in Google Scholar
  • 116 Lijnen HR, Maquoi E, Morange P , et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23 (1) 78-84
    CrossrefPubMedSearch in Google Scholar
  • 117 Lijnen HR. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Thromb Haemost 2005; 93 (5) 816-819
    PubMedSearch in Google Scholar
  • 118 Schäfer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15 (10) 1840-1842
    PubMedSearch in Google Scholar
  • 119 Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26 (10) 2200-2207
    CrossrefPubMedSearch in Google Scholar
  • 120 Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93 (4) 631-640
    PubMedSearch in Google Scholar
  • 121 Alessi MC, Nicaud V, Scroyen I , et al; DESIR Study Group. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. Thromb Haemost 2011; 106 (3) 416-422
    Thieme ConnectPubMedSearch in Google Scholar
  • 122 Declerck PJ, Gils A, De Taeye B. Use of mouse models to study plasminogen activator inhibitor-1. Methods Enzymol 2011; 499: 77-104
    PubMedSearch in Google Scholar
  • 123 Dewilde M, Van De Craen B, Compernolle G , et al. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. J Struct Biol 2010; 171 (1) 95-101
    CrossrefPubMedSearch in Google Scholar
  • 124 Gils A, Meissenheimer LM, Compernolle G, Declerck PJ. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 2009; 102 (3) 609-610
    PubMedSearch in Google Scholar
  • 125 Matsuo O, Lijnen HR, Ueshima S, Kojima S, Smyth SS. A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations. J Thromb Haemost 2007; 5 (4) 680-689
    CrossrefPubMedSearch in Google Scholar
  • 126 Lijnen HR, van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224 (3) 863-871
    CrossrefPubMedSearch in Google Scholar
  • 127 Kawasaki T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts MF. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 2000; 96 (1) 153-160
    PubMedSearch in Google Scholar
  • 128 Van De Craen B, Scroyen I, Abdelnabi R , et al. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. Thromb Res 2011; 128 (1) 68-76
    CrossrefPubMedSearch in Google Scholar
  • 129 Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006; 4 (12) 2710-2715
    CrossrefPubMedSearch in Google Scholar
  • 130 Carmeliet P, Stassen JM, Schoonjans L , et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92 (6) 2756-2760
    CrossrefPubMedSearch in Google Scholar
  • 131 Smith LH, Dixon JD, Stringham JR , et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107 (1) 132-134
    CrossrefPubMedSearch in Google Scholar
  • 132 Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97 (10) 1002-1008
    CrossrefPubMedSearch in Google Scholar
  • 133 Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93 (6) 1825-1830
    PubMedSearch in Google Scholar
  • 134 Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99 (23) 3050-3055
    CrossrefPubMedSearch in Google Scholar
  • 135 Boulaftali Y, Lamrani L, Rouzaud MC , et al. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost 2012; 107 (5) 962-971
    Thieme ConnectPubMedSearch in Google Scholar
  • 136 Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95 (2) 577-580
    PubMedSearch in Google Scholar
  • 137 Matsuno H, Kozawa O, Niwa M , et al. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81 (4) 601-604
    PubMedSearch in Google Scholar
  • 138 Abderrahmani R, François A, Buard V , et al. PAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injury. PLoS ONE 2012; 7 (4) e35740
    CrossrefPubMedSearch in Google Scholar
  • 139 Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106 (4) 491-496
    CrossrefPubMedSearch in Google Scholar
  • 140 Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost 2007; 5 (7) 1500-1508
    CrossrefPubMedSearch in Google Scholar
  • 141 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346 (6279) 74-76
    CrossrefPubMedSearch in Google Scholar
  • 142 Eitzman DT, McCoy RD, Zheng X , et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97 (1) 232-237
    CrossrefPubMedSearch in Google Scholar
  • 143 Narasaki R, Xu Z, Liang Z, Fung LC, Donahue D, Castellino FJ, Ploplis VA. The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice. J Thromb Haemost 2012; 10: 2618-2621
    CrossrefPubMedSearch in Google Scholar
  • 144 Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99 (18) 2440-2444
    CrossrefPubMedSearch in Google Scholar
  • 145 Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005; 3 (7) 1379-1384
    CrossrefPubMedSearch in Google Scholar
  • 146 Nagai N, Van Hoef B, Lijnen HR. Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice. J Thromb Haemost 2007; 5 (8) 1726-1731
    CrossrefPubMedSearch in Google Scholar
  • 147 Andreasen PA. PAI-1—a potential therapeutic target in cancer. Curr Drug Targets 2007; 8 (9) 1030-1041
    CrossrefPubMedSearch in Google Scholar
  • 148 Soff GA, Sanderowitz J, Gately S , et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96 (6) 2593-2600
    CrossrefPubMedSearch in Google Scholar
  • 149 Devy L, Blacher S, Grignet-Debrus C , et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16 (2) 147-154
    CrossrefPubMedSearch in Google Scholar
  • 150 Lambert V, Munaut C, Carmeliet P , et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. Invest Ophthalmol Vis Sci 2003; 44 (6) 2791-2797
    CrossrefPubMedSearch in Google Scholar
  • 151 McMahon GA, Petitclerc E, Stefansson S , et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276 (36) 33964-33968
    CrossrefPubMedSearch in Google Scholar
  • 152 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91 (3) 425-437
    PubMedSearch in Google Scholar
  • 153 Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012; 130 (4) 576-585
    CrossrefPubMedSearch in Google Scholar
  • 154 Lee SH, Eren M, Vaughan DE, Schleimer RP, Cho SH. A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma. Am J Respir Cell Mol Biol 2012; 46 (6) 842-846
    CrossrefPubMedSearch in Google Scholar
  • 155 Watanabe R, Nakajima T, Ogawa M , et al. Effects of pharmacological suppression of plasminogen activator inhibitor-1 in myocardial remodeling after ischemia reperfusion injury. Int Heart J 2011; 52 (6) 388-392
    CrossrefPubMedSearch in Google Scholar
  • 156 Tashiro Y, Nishida C, Sato-Kusubata K , et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 2012; 119 (26) 6382-6393
    CrossrefPubMedSearch in Google Scholar